MannKind | MNKD - Assets


MannKind reported $792.18M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Adma Biologics USD 624.24M 55.56M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Insmed USD 2.26B 96.18M Dec/2025
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
MannKind USD 792.18M 297.54M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 1.18B 3.38M Dec/2025
Novo Nordisk DKK 76.18B 412.98B Jun/2025
Pfizer USD 208.73B 2.64B Sep/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Xencor USD 875.5M 6.68M Dec/2025